Ling H Hua

US Patent:

20030064432, Apr 3, 2003

Filed:

Dec 8, 2000

Appl. No.:

09/734237

Inventors:

J. Rozzell - Burbank CA, US
Peter Bui - El Monte CA, US
Ling Hua - Arcadia CA, US

International Classification:

C07K014/00
C12P021/02
C12N005/06
C07H021/04

US Classification:

435/069100, 435/325000, 435/320100, 536/023100, 530/350000

Abstract:

A synthetic nucleic acid sequence is disclosed, comprising a non-naturally occurring polymer of nucleic acids, having a biological function encoded by the sequence and known from a starting nucleic acid sequence, and having a difference in sequence of at least about 5% between the nucleic acids of the synthetic sequence and the starting sequence. The difference between the nucleic acid sequences results in a different free energy of folding for the synthetic sequence as compared to the starting sequence, such that the synthetic sequence would be expressed better in a selected heterologous host cell than the starting sequence would be if expressed in the same heterologous host cell.

US Patent:

20040115691, Jun 17, 2004

Filed:

Jul 10, 2003

Appl. No.:

10/617998

Inventors:

J. Rozzell - Burbank CA, US
Ling Hua - Arcadia CA, US
Martin Mayhew - Arcadia CA, US
Scott Novick - Santa Clarita CA, US

International Classification:

C12Q001/68
C07H021/04
C12N009/06

US Classification:

435/006000, 435/069100, 435/191000, 435/320100, 435/325000, 536/023200

Abstract:

Mutants of leucine dehydrogenase sequences, formate dehydrogenase sequences and galactose oxidase sequences are provided. An amino acid sequence that is a mutant of a leucine dehydrogenase sequence as described in SEQ ID 2, or its substantial equivalent, contains at least one mutation selected from the group consisting of F102S, V33A, S351T, N145S and like mutations in subsantially equivalent sequences. An amino acid sequence that is a mutant of a formate dehydrogenase sequence as described in SEQ ID 1, or its substantial equivalent, contains at least one mutation selected from the group consisting of D195S, Y196H, K356T and like mutations in subsantially equivalent sequences. An amino acid sequence that is a mutant of a galactose oxidase sequence as described in SEQ ID 3, or its substantial equivalent, contains at least one mutation selected from the group consisting of N25Y, T94A, D216N, R217C, M278T, Y329C, Q406R, Q406L, V492A, V494A, N521S, N535D, T5491, S567T, T578S and like mutations in subsantially equivalent sequences. Deoxyribonucleic acid molecules containing DNA sequences encoding these mutants are also provided.

US Patent:

20050196774, Sep 8, 2005

Filed:

Nov 15, 2004

Appl. No.:

10/989488

Inventors:

J. Rozzell - Burbank CA, US
Peter Bui - El Monte CA, US
Ling Hua - Arcadia CA, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50
C07H021/04

US Classification:

435006000, 702020000, 536023200

Abstract:

A synthetic nucleic acid sequence is disclosed, comprising a non-naturally occurring polymer of nucleic acids, having a biological function encoded by the sequence and known from a starting nucleic acid sequence, and having a difference in sequence of at least about 5% between the nucleic acids of the synthetic sequence and the starting sequence. The difference between the nucleic acid sequences results in a different free energy of folding for the synthetic sequence as compared to the starting sequence, such that the synthetic sequence would be expressed better in a selected heterologous host cell than the starting sequence would be if expressed in the same heterologous host cell.